The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

The Association for Research in Vision and Ophthalmology (ARVO) Foundation has announced Maria Vittoria Cicinelli, MD, Denise ...

Additionally, Unity Biotechnology also announced 3 Yehia Hashad, MD, executive vice president of research and development and ...

The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose ...

Ocular surface discomfort can be problematic after cataract surgery. Italian researchers tested the use of cyclosporine A 0.1 ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.